InvestWiser

Nanexa AB

NANEXANasdaq StockholmHealthcareMarket value 1.9 bn SEK
9.92SEK −0.4%
last day · Price as of 18 November 2026

The answer first

Does Nanexa beat the market?

Yes, Nanexa has beaten the market over the last year.

Nanexa+496.2%Stockholm (OMXSGI)+18.4%
  • The ranking · Quality, value and trend combined

    Better than 92% of Nordic stocks

    • Quality98
    • Value23
    • Trend100

    No. 7 of 195 in healthcare

Max for seven days

Follow Nanexa with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Nanexa

From today, at a price of 9.92 SEK. Write why you follow Nanexa, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Nanexa

Your first answer is free, no account needed.

Do you own Nanexa, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Nanexa and a few more. Free, no card.

Past year against the exchange and Super Stock
Nanexa+439.1%Stockholm (OMXSGI)+18.4%Super Stock+45.9%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Nanexa has risen 496.2% over the past year, including dividends.
  • Overall, Nanexa ranks better than 92% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 95.2%. The price is 29.1% below its peak now.

What do analysts think of Nanexa?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

92

Quality, value and trend together. Better than 92% of Nordic stocks.

No. 7 of 195 in healthcare

Quality98
The company · Fundamentals: the accounts

High A solid company: it earns well on its money and has healthy finances.

No. 9 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.01
  • Asset turnoverSales divided by everything the company owns0.80
  • Return on equityProfit divided by equity+47.6%
  • Cash conversionOperating cash flow divided by profit−0.10

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value23
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 89 of 197 in healthcareTypical in healthcare: 21Typical in the Nordics: 50

  • P/BPrice divided by equity6.3
  • P/SPrice divided by sales7.4
  • P/EPrice divided by earnings13.3
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend100
The share price · Technical: the price trend

High Tailwind in the share price: it has risen more than most over the last year.

No. 1 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months+115.9%
  • 6 months+178.1%
  • 9 months+165.6%
  • 12 months+496.2%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−8.8%
3 years, per year
+145.3%
5 years, per year
+19.1%
10 years, per year
+4.2%
Largest fall, 3 years
−95.2%
From a peak to the bottom
From the peak now
−29.1%
How far the price is from the peak
Volatility, 1 year
130.5%
How much the price swings over a year
Beta, 1 year
0.75
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Nanexa

2 funds we follow own Nanexa. The share is how much of the fund the stock makes up.

  • Norway1
  • Sweden1

From the funds' latest known holdings.

About Nanexa

Nanexa AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 17 employees.

Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, Europe, Asia, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that has completed Phase I trial for the treatment of type 2 diabetes; NEX-18, a drug from azacitidine to treat myelodysplastic syndrome; and NEX-20, a drug from lenalidomide for the treatment of multiple myeloma.

See the full analysis of Nanexa.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market